Market Assessment, Chronic Heart Failure: LCZ 696 and ivabradine Current Treatment US 2016 Report

Chronic heart failure patients are subject to high rates of mortality and morbidity and frequent readmissions to the hospital mean that chronic heart failure also represents a significant healthcare burden. The Current Treatment Chronic Heart Failure (US) report offers a snapshot of how U.S. cardiologists prescribe currently available therapies, provides insight into the factors driving such prescribing habits, as well as anticipated future changes in prescribing practices.

Back to all Market Assessment reports

Contact us

Investors

Careers

Login

Chronic Heart Failure: LCZ-696 and ivabradine | Current Treatment | US | 2016

Related Market Assessment Reports

Special Topics | Comorbidities in Major Depressive Disorder | US

Venous Thromboembolism – Landscape & Forecast – Disease Landscape & Forecast

Dry Eye – Access & Reimbursement – Detailed, Expanded Analysis (US)

Vitiligo – Executive Insights – Executive Insights (US)

Obesity/Overweight – Unmet Need – Detailed, Expanded Analysis (US/EU)